HEC Pharm Co., Ltd. — patent litigation as defendant

HEC Pharm Co., Ltd.

2 cases as defendant.

Cases

Active

2 closed

Filed

—

Top venue

Fed. Cir.

1 case

Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc. et al.

Reversed on rehearing; claims invalid

Docket:: 21-1070
Court:: U.S. Court of Appeals for the Federal Circuit

Patents:9187405

π Novartis Pharmaceuticals Corp.Δ Accord Healthcare, Inc.Δ HEC Pharm Co., Ltd.

Appeal from D. Del. 1:18-cv-01043. The Federal Circuit first affirmed validity and infringement on January 3, 2022, then on rehearing vacated and reversed, holding the '405 patent claims invalid for lack of written description (38 F.4th 1013). Rehearing en banc was denied and mandate issued approximately October 18, 2022.

Novartis Pharmaceuticals Corp. v. HEC Pharm Co., Ltd.

Certiorari denied

Docket:: 22-671
Court:: Supreme Court of the United States

Patents:9187405

π Novartis Pharmaceuticals Corp.Δ HEC Pharm Co., Ltd.

Petition for certiorari from the Federal Circuit's invalidation of the '405 patent; emergency stay of mandate was granted by Chief Justice Roberts on 2022-09-29; certiorari was denied (143 S. Ct. 1748).